Autres langues Nabriva Therapeutics plc

Actions

NBRVF

IE000OZRGNV6

Marché Fermé - OTC Markets Autres places de cotation 15:33:08 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,0001 ^USD	0,00%		0,00%	+9 900,00%

2023	Nabriva Therapeutics plc publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023	CI
2023	Sumitomo Pharma Co. (TSE:4506) a acquis les actifs et les droits liés à la léfamuline en Chine, à Hong Kong, à Macao et à Taïwan auprès de Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH et Nabriva Therapeutics Ireland Dac pour un montant de 15 millions de dollars.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	19/10/23
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	31/07/23
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	31/07/23
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	24/07/23
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	10/07/23
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	07/07/23
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	07/07/23
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	17/04/23
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	17/04/23
Nabriva Therapeutics : Material Agreement - Form 8-K	06/02/23
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	06/02/23
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	20/01/23
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	20/01/23
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	09/01/23
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	09/01/23
Nabriva Therapeutics Provides Corporate Update	09/01/23
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	06/01/23
Sector Update: Healthcare Stocks Rise Friday, Mostly Trail Other Sectors	06/01/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nabriva Therapeutics plc

Actions

NBRVF

IE000OZRGNV6

Autres langues

Filtres